NasdaqGS:MEDPLife Sciences
Medpace Holdings (MEDP) Is Down 21.0% After Mixed 2026 Guidance and Elevated Trial Cancellations
In February 2026, Medpace Holdings reported past fourth-quarter 2025 results showing revenue of US$708.45 million and GAAP diluted EPS of US$4.67, alongside full-year 2025 revenue of US$2.53 billion and net income of US$451.12 million.
The company also issued 2026 guidance calling for revenue of US$2.76–US$2.86 billion and GAAP diluted EPS of US$16.68–US$17.50, while acknowledging elevated trial cancellations and a softer book-to-bill ratio despite strong new business awards.
We’ll now...